4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity
- 作者: Liu F.1, Tang B.1, Liu H.1, Li L.1, Liu G.1, Cheng Y.1, Xu Y.1, Chen W.1, Huang Y.1
-
隶属关系:
- ,
- 期: 卷 16, 编号 12 (2016)
- 页面: 1652-1664
- 栏目: Oncology
- URL: https://kld-journal.fedlab.ru/1871-5206/article/view/695359
- DOI: https://doi.org/10.2174/1871520616666160404113141
- ID: 695359
如何引用文章
全文:
详细
4-Anilinoquinazoline derivatives possess high anti-cancer activities. Many of them are highly selective tyrosine kinase inhibitors (TKI), particularly against epidermal growth factor receptor (EGFR). EGFRs are overexpressed or mutated in most carcinomas and are required for tumor progression. The efficacy of EGFR-targeted anti-tumor drugs is impaired by drug-induced acquired resistance. Therefore, there is urgency to find better anti-cancer agents with novel effects on EGFR. 4-Anilinoquinazolines are small molecule EGFR inhibitors that have been synthesized and assessed for their anti-tumor bioactivity. In this paper, we review the 4-anilinoquinazoline derivatives with EGFR inhibitor activity reported in recent years.
作者简介
Fang Liu
,
Email: info@benthamscience.net
Baoding Tang
,
Email: info@benthamscience.net
Hao Liu
,
Email: info@benthamscience.net
Leina Li
,
Email: info@benthamscience.net
Gang Liu
,
Email: info@benthamscience.net
Yun Cheng
,
Email: info@benthamscience.net
Yan Xu
,
Email: info@benthamscience.net
Wenwen Chen
,
Email: info@benthamscience.net
Yinjiu Huang
,
Email: info@benthamscience.net
补充文件
